As a result of the July 2020 update to the FDA's guidance document, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue- Based Products: Minimal Manipulation and Homologous Use," FDA is extending the TRIP program through March 31, 2021.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/35fzlpz
No comments:
Post a Comment